Takeover talks advanced. Qiagen stock traded 1.15 percent below its prior close

Published on 10/08/2026 at 11:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue beat consensus at USD 535.04 million by USD 7.54 million. Qiagen stock costs EUR 39.66 on October 8, 2026 after EUR 40.12.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Takeover discussions involving Qiagen and potential buyers had advanced in reports dated October 2, 2026, while Qiagen stock was trading at EUR 39.66 at Lang & Schwarz on October 8, 2026, down 1.15 percent versus the prior close of EUR 40.12. Ground News said the discussions involved private-equity firms and a U.S. molecular-testing buyer considering a premium offer.

Takeover interest meets valuation questions

The report adds a strategic layer to Qiagen's operating story, but it does not establish that a transaction will occur. The same coverage described the discussions as involving at least one potential buyer, making the report an event to monitor rather than a completed deal.

Qiagen's market capitalization was USD 9.2 billion as of October 7, 2026, with a 52-week range of USD 32.53 to USD 57.82. The euro reference price therefore remains separate from the company's U.S.-dollar valuation context.

Second-quarter sales beat expectations

Zacks reported that Qiagen's second-quarter 2026 net sales reached USD 535.04 million, up USD 7.54 million from the USD 527.50 million consensus estimate. Adjusted earnings per share came to USD 0.62, which was 3.3 percent above consensus and 3.3 percent higher than the year-ago period.

The quality of that growth was mixed. Sample technologies revenue rose 9.0 percent year over year to USD 182.0 million, while diagnostic solutions revenue fell 1.0 percent to USD 204.0 million and PCR revenue declined 7.0 percent to USD 74.0 million, according to Zacks.

AI launch adds a growth angle

On October 7, 2026, Qiagen introduced IPA Investigator and the Qiagen Discovery Platform for research and drug discovery. BioSpace reported that the tools apply artificial intelligence to biological and genomic data while keeping supporting evidence visible to researchers.

For investors, the contrast is clear: second-quarter revenue exceeded consensus by USD 7.54 million, but the stock still depends on execution in diagnostics, sample technologies and digital insights. The takeover report adds optionality, while the operating figures provide the measurable test.

Qiagen stock trades below its prior close

Qiagen stock was trading at EUR 39.66 at Lang & Schwarz on October 8, 2026 at 11:12 a.m. CEST, down 1.15 percent versus the prior close of EUR 40.12. Qiagen is listed on the NYSE under ticker QGEN, and its primary quotation currency is USD, as identified in the company release published by BioSpace. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.